Accelerating the Commercialization of Next-Generation Nanomedicine
With the rapid advancements in mRNA vaccines, siRNA therapeutics, gene editing, and cancer immunotherapy, liposomes and lipid nanoparticles (LNPs) have become the cornerstone of modern drug delivery, enhancing drug stability, bioavailability, and targeted delivery.
As a global leader in drug delivery technologies, Litchlab provides state-of-the-art cGMP-grade liposome and LNP manufacturing, offering end-to-end solutions from formulation screening and process optimization to large-scale clinical and commercial production.
By leveraging advanced delivery systems and a rigorous quality control framework, Litchlab is driving the successful translation of RNA therapeutics, targeted oncology treatments, vaccines, and gene-editing therapies from the laboratory to the market.
LNP & Liposomes: The Future of Precision Drug Delivery
LNPs and liposomes are engineered nanocarriers that effectively encapsulate both hydrophilic and hydrophobic drugs, optimize pharmacokinetics, and improve cellular uptake, making them indispensable for RNA therapeutics, gene editing, protein/peptide delivery, vaccines, and targeted oncology treatments.
Key Advantages of Litchlab’s cGMP Liposome & LNP Manufacturing
Technology Feature | Litchlab Solution | Applications |
Precise Particle Size Control (50-200nm) | Microfluidics-based production ensures uniformity and enhanced cellular uptake | RNA therapeutics, gene editing |
High Drug Encapsulation Efficiency (>95%) | Optimized lipid composition enhances stability of mRNA, siRNA | mRNA vaccines, siRNA delivery |
PEGylated Liposomes | Surface PEGylation reduces immune clearance and extends circulation time | Long-acting RNA drugs, cancer immunotherapy |
Targeted Functionalization (Antibody/Aptamer Conjugation) | Enhances tumor-specific delivery, minimizes off-target effects | Targeted therapy, gene editing |
cGMP Large-Scale Manufacturing | High-pressure extrusion and microfluidic technologies for seamless scale-up | Clinical and commercial drug production |
Litchlab’s cGMP Manufacturing: Delivering High-Quality Nanomedicines
Litchlab operates a state-of-the-art cGMP manufacturing facility, meeting the strictest FDA, EMA, and NMPA regulatory standards to support preclinical, clinical, and commercial-scale LNP and liposome production.
Litchlab’s cGMP Manufacturing Capabilities
✅ LNP & Liposome Formulation and Process Development
Microfluidics, high-pressure extrusion, and thin-film hydration for precise particle engineering
Compatible with mRNA, siRNA, ASO, CRISPR/Cas9 therapeutics
✅ cGMP-Compliant Production and Quality Control
Fully compliant with FDA, EMA, and NMPA regulatory guidelines
Stringent quality control (QC): DLS, HPLC, TEM characterization
Animal-free and endotoxin-free formulations ensuring product safety
✅ Flexible Scale-Up from Lab to Commercial Production
Small-scale R&D batches (mg-gram scale)
Clinical trial batches (gram-kg scale)
Full-scale cGMP commercial production (kg-scale and beyond)
Key Applications of Litchlab’s LNP & Liposome Technologies
✅ RNA Therapeutics (mRNA / siRNA / ASO)
mRNA Vaccine Delivery: Optimized LNP carriers enhance translation efficiency and immunogenicity
siRNA Targeted Delivery: Improved siRNA stability and gene silencing efficacy
ASO (Antisense Oligonucleotide) Delivery: Increased bioavailability for rare disease treatments
✅ Targeted Oncology Therapies
Liposomal Chemotherapy (e.g., Liposomal Doxorubicin): Reduced toxicity, improved therapeutic efficacy
siRNA + Small Molecule Co-Delivery: Precision gene modulation for enhanced treatment outcomes
Immunotherapy Nanocarriers: Enhancing PD-1/PD-L1 blockade for superior T-cell activation
✅ Vaccine Delivery
mRNA Vaccines (COVID-19, Flu, Personalized Cancer Vaccines): Enhanced immune response and stability
Protein-Based Vaccines in Liposomes: Improved antigen presentation and protection
✅ Gene Editing & Rare Disease Treatments
CRISPR/Cas9 Delivery: Higher gene-editing efficiency with reduced off-target effects
Liposomal Sustained-Release Systems: Long-term delivery for improved patient compliance
Litchlab: Partnering with Global Biopharma to Accelerate RNA Therapeutics & Precision Medicine
As RNA therapeutics, gene editing, and targeted oncology therapies continue to evolve, Litchlab’s world-class cGMP liposome & LNP manufacturing capabilities provide biopharma companies, biotech firms, and vaccine developers with a seamless transition from research to commercial production.
Formulation Optimization: Custom LNP/liposome formulations for enhanced delivery
Process Scale-Up & GMP Production: From small-batch development to full-scale manufacturing
Targeted Functionalization: Antibody and aptamer conjugation for improved specificity
Stability Enhancement: Ensuring long-term integrity of RNA drugs and monoclonal antibodies
Regulatory-Compliant QC & Manufacturing: Meeting global cGMP quality standards
Litchlab is at the forefront of next-generation RNA therapeutics, gene editing, and precision medicine, driving clinical translation and commercialization to bring safer, more effective treatments to patients worldwide.
For more information, please feel free to contact us at:
E-Mail:RD1@Litchlab.com
